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Ca2+/calmodulin-dependent protein kinase II
Aims: The clinical beneﬁts of angiotensin II type 1 (AT1) receptor blockers (ARB) in heart failure (HF) include
cardiac anti-remodeling and improved ventricular function. However, the cellular mechanisms underlying
the beneﬁts of ARB on ventricular function need to be better clariﬁed. In the present manuscript, we evaluated
the effects of AT1 receptor blockade on the net balance of Ca2+ handling proteins in hearts of mice lackingα2A
and α2C adrenoceptors (α2A/α2CARKO), which develop sympathetic hyperactivity (SH) induced-HF.
Main methods: A cohort of male wild-type (WT) and congenic α2A/α2CARKO mice in a C57BL6/J genetic
background (5–7 mo of age) was randomly assigned to receive either placebo or ARB (Losartan, 10 mg/kg for
8wks). Ventricular function (VF) was assessed by echocardiography, and cardiac myocyte width and
ventricular ﬁbrosis by a computer-assisted morphometric system. Sarcoplasmic reticulum Ca2+ ATPase
(SERCA2), phospholamban (PLN), phospho-Ser16-PLN, phospho-Thr17-PLN, phosphatase 1 (PP1), Na+–Ca2+exchanger (NCX), Ca2+/calmodulin-dependent protein kinase II (CaMKII) and phospho-Thr286-CaMKII were
analyzed by Western blot.
Key ﬁndings: α2A/α2CARKO mice displayed ventricular dysfunction, cardiomyocyte hypertrophy and cardiac
ﬁbrosis paralleled by decreased SERCA2 and increased phospho-Thr17-PLN, CaMKII, phospho-Thr286-CaMKII
and NCX levels. ARB induced anti-cardiac remodeling effect and improved VF inα2A/α2CARKO associated with
increased SERCA2 and phospho-Ser16-PLN levels, and SERCA2:NCX ratio. Additionally, ARB decreased
phospho-Thr17-PLN levels aswell as reestablishedNCX, CaMKII and phospho-Thr286-CaMKII towardWT levels.
Signiﬁcance: Altogether, these data provide new insights on intracellular Ca2+ regulatory mechanisms
underlying improved ventricular function by ARB therapy in HF.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Heart failure (HF) is a common leading cause of mortality
worldwide. During HF progression, the heart is in constant peril of
damage from pathological stresses, such as neurohumoral over-
activation (Bacurau et al., 2009; Barki-Harrington et al., 2003; Brum
et al., 2006).
Several lines of evidence suggest that sustained renin angiotensin
system (RAS) activation plays deleterious effects in the heart since
increased cardiac angiotensin II levels lead to cardiomyocyte
hypertrophy and myocardial ﬁbrosis (Dostal, 2000; Ferreira et al.,
2008a; Leenen et al., 2001), and further contribute to HF establish-
ment (Palaniyandi et al., 2009). The beneﬁt of RAS inhibition in HF has
been demonstrated in several randomized clinical trials where ARB-e Esporte da Universidade de
ento do Corpo Humano, Av.
P 05508-900– Brazil. Tel.: +55
sevier OA license.treated HF patients displayed reduced morbidity and mortality (Pitt
et al., 1995), and showed a wide range of desirable hemodynamic
outcomes (Sweet and Rucinska, 1994). Besides the well-known
cardiac anti-remodeling effect of ARB therapy, some clinical trials
and experimental studies have shown that sustained ARB therapy also
improves ventricular function in HF patients (Crozier et al., 1995; Qing
and Garcia, 1992). However, the molecular mechanisms related to
ARB therapy-mediated improved ventricular function in HF remains
elusive.
Considering that cardiac function is strongly coupled with Ca2+
transient in the heart, a positive effect of ARB on cardiac Ca2+-
handling proteins in HF might be a potential molecular mechanism
involved in ARB improved ventricular function. The process involved
in excitation–contraction coupling in the heart involves Ca2+ release
from the sarco/endoplasmic reticulum (SR) initiated by membrane
depolarization and subsequent Ca2+ inﬂux via L-type Ca2+ channels.
This triggers further SR-Ca2+ release channels (Ryanodine receptors,
RyR) via Ca2+-induced Ca2+ release and produces Ca2+ sparks,
triggering cardiomyocyte contraction. After contraction, sarcoplasmic
reticulum Ca2+ ATPase (SERCA) and Na+–Ca2+ exchanger (NCX)
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sequestering Ca2+ from the sarcoplasm or extruding it outside the
cell, respectively.
Over the last decades, several studies have shown that ventricular
dysfunction is related to changes in phosphorylation status of sarco/
endoplasmic proteins (LeWinter, 2005; Paulino et al., 2010), reduced
sarcoplasmic reticulum Ca2+ ATPase (SERCA2) function (Pogwizd
et al., 2001), upregulation of Na+–Ca2+ exchanger (NCX) (Pogwizd
and Bers, 2002) and diastolic Ca2+ leak via ryanodine receptors (Ai
et al., 2005). We have reported that Ca2+ handling impairment is
associated with ventricular dysfunction and HF progression (Bueno
et al., 2010; Medeiros et al., 2008), where both pharmacological
(Bartholomeu et al., 2008) and non-pharmacological (Vanzelli et al.,
2010) therapies improved cardiac function by minimizing Ca2+
transient abnormalities. Therefore, Ca2+ handling impairment often
comes with the development of HF and should be considered a prime
target for potential new therapeutic approaches.
We have previously shown that mice lacking both α2A/α2C-
adrenoceptors (α2A/α2CARKO) display sympathetic hyperactivity-
related cardiac dysfunction and pathological ventricular remodeling,
which ultimately lead to HF and increased mortality rate at 7 months
of age (Brum et al., 2002). Lately, we also demonstrated that cardiac
abnormalities observed in α2A/α2CARKO mice were accompanied
by over activation of cardiac RAS and impaired intracellular Ca2+
handling (Ferreira et al., 2008a; Pereira et al., 2009; Rolim et al., 2007).
Thus, these mice provide a good model for better understanding the
effect of cardiac RAS activation on Ca2+ handling proteins expression
proﬁle in HF. Therefore, the present study was undertaken to evaluate
the effects of ARB therapy on the net balance of Ca2+ handling
proteins in a genetic animal model of SH-induced HF. We hypothe-
sized that ARB treatment would reestablish the net balance of Ca2+




A cohort of male congenic α2A/α2CARKO mice in a C57BL6/J
genetic background and their wild-type controls (WT) were studied
at 5 and 7 mo of age. At 7 mo of age, α2A/α2CARKO mice present
severe cardiac dysfunction associated with exercise intolerance and
increased mortality rate (Brum et al., 2002). Mice were maintained in
a 12:12-h light–dark cycle and temperature-controlled environment
(22 °C) with free access to standard laboratory chow (Nuvital
Nutrientes S/A, Curitiba, PR, Brazil) and tap water. This study was
performed according to ethical principles in animal research adopted
by Brazilian College of Animal Experimentation (www.cobea.org.br).
In addition, this study was approved by the University of São Paulo
Ethical Committee (CEP#059).
AT1 receptor blockade treatment
To test whether increased cardiac RAS would be functionally
involved in Ca2+ handling of advanced-stage cardiomyopathy, α2A/
α2CARKO mice were randomly assigned to receive either saline
(placebo) or AT1 blocker (ARB, losartan, 10 mg/kg in drinking water)
for 8 wk (from 5 to 7 mo of age). ARB treatment did not change blood
pressure, cardiac function, and structure of WT mice (data not
shown). Therefore, we used only one control WT group for further
comparisons with α2A/α2CARKO groups.
Cardiovascular measurements
Heart rate (HR) and blood pressure (BP) were determined
noninvasively using a computerized tail-cuff system (BP 2000 VisitechSystems, Apex, NC, USA) described elsewhere (Johns et al., 1996).
Mice were acclimatized to the apparatus during daily sessions over
4 days, one week before starting the experimental period.
Noninvasive cardiac function was assessed by two-dimensional
guided M-mode echocardiography, in halothane-anesthetized WT
and α2A/α2CARKO mice, before and after the experimental period.
Brieﬂy, mice were positioned in the supine position with front paws
wide open, and an ultrasound transmission gel was applied to the
precordium. Transthoracic echocardiography was performed using
an Acuson Sequoia model 512 echocardiographer equipped with a
14-MHz linear transducer. Left ventricle systolic function was esti-
mated by fractional shortening (FS) as follows: FS (%)=[(LVEDD−
LVESD)/LVEDD]×100, where, LVEDD means left ventricular end-
diastolic diameter, and LVESD means left ventricular end-systolic
diameter.
Graded treadmill exercise test
Exercise capacity, estimated by total distance run, was evaluated
with a graded treadmill exercise protocol as previously described
(Ferreira et al., 2010; Ferreira et al., 2007). Brieﬂy, after being adapted
to treadmill exercises over 1 wk (10 min each session), mice were
placed in the exercise streak and allowed to acclimatize for at least
30 min. Exercise intensity was increased by 3 m/min (6–33 m/min)
every 3 min at 0% grade until exhaustion.
Structural analysis
All mice were killed and their tissues were harvested. Cardiac
chambers were then ﬁxed by immersion in 4% buffered formalin and
embedded in parafﬁn for routine histological processing. Sections
(4 μm) were stained with hematoxylin and eosin for examination
by light microscopy. Only nucleated cardiac myocytes from areas of
transversely cut muscle ﬁbers were included in the analysis.
Quantiﬁcation of left ventricular ﬁbrosis was achieved by Sirius
red staining. Cardiac myocyte width and ventricular ﬁbrosis were
measured in the left ventricle free wall with a computer-assisted
morphometric system (Leica Quantimet 500, Cambridge, UK).
Immunoblot
Immunoblots of heart homogenates from 7-mo-old WT and α2A/
α2CARKO were performed according to Towbin et al. (Towbin et al.,
1979). Brieﬂy, liquid nitrogen frozen tissues were homogenized in a
buffer containing 1 mM EDTA, 1 mM EGTA, 2 mM MgCl2, 5 mM KCl,
25 mM HEPES (pH.7.5), 100 μM PMSF, 2 mM DTT, 1% Triton X-100,
and protease inhibitor cocktail (1:100, Sigma-Aldrich; St. Louis, MO
USA). Samples were loaded and subjected to SDS-PAGE in poly-
acrylamide gels (10%). After electrophoresis, proteins were electro-
transferred to nitrocellulose membrane (Amersham Biosciences;
Piscataway, NJ USA). Equal loading of samples (60 μg) and even
transfer efﬁciency were monitored with the use of 0.5% Ponceau
S staining of the blotted membrane. The blotted membrane was then
incubated in a blocking buffer (5% nonfat dry milk, 10 mM Tris–HCl,
pH 7.6, 150 mM NaCl, and 0.1% Tween 20) for 2 h at room tem-
perature and then incubated overnight at 4 °C with mouse mono-
clonal antibodies to SERCA2 (1:2500), PLN (1:500), and NCX
(1:2000), obtained from Afﬁnity BioReagents (Golden, CO USA);
rabbit polyclonal antibody to protein phosphatase type 1 (PP1)
(1:1000) was obtained from Upstate Biotechnology (Lake Placid, NY);
phospho-Ser16-PLN (1:5000) and phospho-Thr17-PLN (1:5000) were
obtained from Badrilla (Leeds, UK); CaMKII and phospho-Thr286-
CaMKII were obtained from Cell Signaling Technology (Beverly, MA
USA). Binding of the primary antibody was detected with the use
of peroxidase-conjugated secondary antibodies (anti-rabbit or anti-
mouse, 1:5000, for 1.5 h at room temperature) and developed using
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USA) detected by autoradiography. Quantiﬁcation analysis of blots
was performed with the use of Scion Image software (Scion based on
National Institutes of Health ImageJ, USA). Samples were normalized
to relative changes in GAPDH levels and expressed as percentage of
control group.
Statistical analysis
Data are presented as means±SE. For fractional shortening, HR,
BP, distance run, body weight and LVEDD measurements, compari-
sons of ARB-treated α2A/α2CARKO, placebo-treated α2A/α2CARKO and
WT control mice were performed by two-way analysis of variance
(ANOVA) for repeated measurements with a post-hoc testing by
Duncan. For cardiac structural analysis, lung wet/dry ratio and protein
expression levels, comparison among groups were performed by one-
way ANOVAwith a post-hoc testing by Duncan. Statistical signiﬁcance
was considered achieved when the value of P was b0.05.
Results
Effect of ARB treatment on exercise tolerance, hemodynamic and cardiac
structure and function
Similar to our previous ﬁndings (Rolim et al., 2007), α2A/α2CARKO
mice displayed exercise intolerance when compared with age-
matched WT mice before treatment period (5 mo-old) (Table 1). Of
interest, ARB therapy improved exercise capacity in α2A/α2CARKO
mice toward WT mice values (Table 1) whereas placebo-treated α2A/
α2CARKO mice presented pronounced exercise intolerance compared
to before treatment period (5 mo-old). Baseline HR was higher in
placebo- and ARB-treated α2A/α2CARKO mice compared to WT mice,
while systolic BP remained unchanged. However, ARB-treated α2A/
α2CARKO mice displayed a signiﬁcant reduction in HR compared to
placebo-treated α2A/α2CARKO group (7 mo-old).
FS was signiﬁcantly lower in α2A/α2CARKO mice compared to
WT mice before treatment period (5 mo-old). Eight weeks of ARB
treatment increased α2A/α2CARKO FS toward WT levels (Fig. 1A).
Regarding of cardiac remodeling, placebo-treated α2A/α2CARKO mice
displayed increased LVESD (Table 2), cardiomyocyte hypertrophy
(Fig. 1B) and more than two-fold increase of cardiac collagen content
(Fig. 1C) compared to age-matched WT mice. ARB treatment nor-
malized LVESD, cardiomyocyte width (Fig. 1B) and collagen content
(Fig. 1C) in α2A/α2CARKO mice.
Expression of proteins involved in intracellular Ca2+ handling
Oncewe have previously demonstrated that the expression of Ca2+
handling proteins is impaired in α2A/α2CARKO mice (Medeiros et al.,
2008), here we investigated whether sustained ARB therapy would
restore their expression proﬁle in HF.Table 1
Physiological parameters in wild type and α2A/α2C ARKO mice.
Pre-treatment
WT ARKO Placebo A
Body weight, g 29.9±0.4 28.0±0.5 28
Distance run, m 408±11 310±14† 2
Heart rate, bpm 590±12 650±12* 6
Blood pressure, mm Hg 108±3 114±2 1
Lung wet/dry ratio – – –
Body weight, distance run, heart rate and blood pressure before and after 8 weeks of ARB trea
presented as means±SEM. and Pb0.05 vs. pre-treatment; *Pb0.05 vs. WT mice; †Pb0.05 vAs expected, SERCA2 levels were signiﬁcantly reduced in placebo-
treated α2A/α2CARKOmice compared to WTmice, while ARB not only
reestablished SERCA2 expression but increased it above WT levels
(Fig. 2A–B). In addition, NCX expression was increased in placebo-
treated α2A/α2CARKO mice whereas ARB reduced NCX expression
toward WT levels (Fig. 2A,C). As sarcoplasmic Ca2+ content depends
upon the Ca2+ reuptake by SERCA2 relative to transsarcolemmal Ca2+
extrusion by NCX, we calculated the SERCA2:NCX ratio for all groups
studied and found that ARB signiﬁcantly increased SERCA2:NCX ratio
in α2A/α2CARKO mice compared to placebo-treated α2A/α2CARKO
mice (Fig. 2A,D).
Since SERCA activity is PLN-regulated, we further investigated
whether PLN protein kinase A (PKA)- and CaMKII-phosphorylation
sites (Ser16 and Thr17 residues, respectively) were altered in HF.
Phospho-Ser16-PLN levels were increased in placebo-treated α2A/
α2CARKO mice compared to WT group (Fig. 3A–B). ARB-treated α2A/
α2CARKO mice displayed a further increase in phospho-Ser16-PLN
levels compared with other groups (Fig. 3A–B). Phospho-Thr17-PLN
expression was increased in placebo-treated α2A/α2CARKO mice
(Fig. 3A,C) and ARB dramatically reduced those levels toward WT
values (Fig. 3A,C). No signiﬁcant changes were found for PP1 protein
levels among groups (Fig. 3A,D).
α2A/α2CARKO mice displayed higher expression of CaMKII
(Fig. 4B) than WT mice. In addition, ARB was efﬁcient in reducing
CaMKII protein levels toward WT mice values (Fig. 4A–B). Phospho-
CaMKII expression was also increased in α2A/α2CARKO mice whereas
ARB treatment decreased it to WT mice levels (P=0.08) (Fig. 4A,C).Discussion
Heart failure is a progressive disorder that involves decreased
cardiac output associated with neurohumoral activation (Goldsmith,
2004). It has been demonstrated that RAS and sympathetic nervous
system over activation exert a direct deleterious effect on the heart,
ultimately leading to cardiac dysfunction and pathological ventricular
remodeling (Bacurau et al., 2009; Brum et al., 2002; Oliveira et al.,
2009). In order to counteract the aforementioned effects, pharmaco-
logical and non-pharmacological therapies, such as β-adrenergic
receptor blocker, AT1-receptor antagonist and exercise training have
been developed (Mudd and Kass, 2008). In the present investigation,
we aimed to evaluate the effects of ARB therapy on the net balance of
Ca2+ handling proteins in a genetic animal model of sympathetic
hyperactivity-induced HF.
The novel ﬁnding of the present study is that, besides its effect on
cardiac remodeling, ARB treatment in α2A/α2CARKO mice increased
cardiac expression of SERCA2 and reduced NCX levels toward WT
values. In addition, ARB-treated α2A/α2CARKO mice displayed an
increased phospho-Ser16-PLN expression while decreased phospho-
Thr17-PLN, CaMKII and phospho-Thr286-CaMKII protein levels com-
pared to placebo-treated α2A/α2CARKO mice. These outcomes were
accompanied by improved ventricular function, represented byPost-treatment
RKO ARB WT ARKO Placebo ARKO ARB
.8±0.3 30.9±0.4 28.7±0.5 28.2±0.6
85±7† 366±19 254±24&* 341±18&†
51±8* 591±14 717±7&* 663±15*†
12±2 110±3 112±2 108±3
4.6±0.1 7.6±0.4* 5.3±0.4*†
tment. Lung wet/dry ratio was assessed only after 8 weeks of ARB treatment. Values are
s. placebo-treated ARKO mice.
Fig. 1. ARB therapy re-establishes cardiac function and promotes cardiac anti-remodeling effects in HF. (A) Fraction shortening in WT and ARKO mice before (open bars) and after
(solid bars) ARB treatment. Note that ARKOmice presented decreased FS when compared withWTmice. ARB treatment restored FS in ARKOmice. Data are presented asmeans±SE.
(B) Representative photomicrographs and quantitative analysis of cardiac myocyte width (400×) and (C) cardiac collagen content (200×) in 7-mo-oldWT and ARKOmice (placebo-
and ARB-treated). Note that ARKO mice presented increased cardiac myocyte cross-sectional diameter paralleled by ventricular ﬁbrosis. ARB treatment decreased cardiac myocyte
width and prevented ventricular ﬁbrosis in ARKO mice. Data are presented as means±SE. *Pb0.05 vs. pre-treatment; †Pb0.05 vs. WT; ‡Pb0.05 vs. placebo-treated ARKO mice.
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as depicted by decreased cardiomyocyte width and diminished
collagen content (Fig. 1).Table 2
Echocardiographic measurements in wild type and α2A/α2C ARKO mice.
Pre-treatment
WT ARKO Placebo ARKO AR
LVESD, mm 3.01±0.07 3.33±0.03* 3.50±0.
LVEDD, mm 3.88±0.08 3.91±0.04 4.05±0.
IVSs, mm 0.92±0.03 0.77±0.04* 0.76±0.
IVSd, mm 0.66±0.02 0.60±0.02 0.64±0.
LVPWs, mm 0.93±0.03 0.77±0.03* 0.73±0.
LVPWd, mm 0.66±0.02 0.60±0.02# 0.61±0.
HR, bpm 466±.7 446±14 466±10
Left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (L
thickness at diastole (IVSd), left ventricular posterior wall thickness at systole (LVPWs), left v
ARB treatment. Values are presented as means±SEM. *Pb0.05 vs. WT mice; † vs. placebo-tOver the past decades, it has been demonstrated that human
failing hearts display impaired intracellular Ca2+ handling due, at
least in part, to reduced expression and activity of SERCA2 proteinPost-treatment
B WT ARKO Placebo ARKO ARB
07*† 3.0±0.08 3.5±0.08* 3.0±0.13†
06# 3.8±0.09 4.1±0.10# 3.8±0.13‡
02* 0.85±0.03 0.89±0.03 0.86±0.07
02 0.66±0.02 0.67±0.02 0.63±0.04
02* 0.85±0.03 0.88±0.03 0.86±0.07
01 0.66±0.02 0.67±0.02 0.66±0.03
468±12 448±12 458±13
VEDD), interventricular septum thickness at systole (IVSs), interventricular septum
entricular posterior wall at diastole (LVPWd) and heart rate before and after 8 weeks of
reated ARKO mice. # P=0.07 vs. WT mice; ‡ vs. placebo-treated ARKO mice.
Fig. 2. ARB treatment increases cardiac SERCA2 protein levels in HF. (A) Representative blots of SERCA2, NCX and GAPDH, (B) SERCA2 and (C) NCX protein levels and (D) SERCA2:
NCX ratio in WT, placebo- and ARB-treated ARKO mice. Note that placebo-treated ARKO mice presented decreased SERCA2 and increased NCX protein levels. In addition, ARB
treatment increased SERCA2 protein levels and SERCA2:NCX ratio in ARKO mice. Data are presented as means±SE. *Pb0.05 vs. WT; †Pb0.05 vs. placebo-treated ARKO mice.
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responsible for calcium reuptake to SR. In fact, SERCA2 dysfunction
results in elevated cytoplasmic Ca2+ concentration and further
diastolic dysfunction. Our previous studies have shown that either
β-adrenergic receptor blocker or exercise training signiﬁcantly
increased cardiac SERCA2 protein levels in HF mice, which was
accompanied by improved intracellular Ca2+ transient and cardiac
function (Bartholomeu et al., 2008; Rolim et al., 2007). Interestingly,
exercise training also decreased cardiac RAS activation in heart
failure mice (Pereira et al., 2009), which could have contributed to
improved Ca2+ handling and cardiac function in exercised HF mice.
Here we showed that sustained ARB therapy also restored SERCA2
expression and improved cardiac function in a HF model that
displays cardiac RAS over activation. These data strengthen the
contribution of RAS inhibition to cardiac function re-establishment
by regulating intracellular Ca2+ handling. Whether these effects
are directly mediated by cardiac effects of ARB therapy or by its
secondary to non-cardiac effects remain to be elucidated. Cytoplas-
mic Ca2+ concentration might also be modulated by NCX, an
antiporter membrane protein involved in Ca2+ removal to extracel-
lular milieu. Previous investigations have shown that increased NCX
expression in HF patients is responsible, at least in part, for an even
lower SR Ca2+ load, indicating that it could contribute to contractile
dysfunction (Lu et al., 2002; Mace et al., 2003). Our ﬁndings showed
that α2A/α2CARKO mice displayed increased NCX protein levels,
whereas ARB treatment reduced its levels toward WT values. This
effect may result in an improved Ca2+ handling in failing hearts. In
fact, we have previously demonstrated that β-antagonist treatmentdecreased cardiac NCX expression and improved Ca2+ transient
dynamics in α2A/α2CARKO mice (Bartholomeu et al., 2008).
Several studies have shown that sympathetic hyperactivity leads
to downregulation of β1-adrenoceptor (AR) and uncoupling of β2-AR,
which is accompanied by a desensitization of PKA and increased
CaMKII signaling pathways (Palermo et al., 1996; Pogwizd et al.,
2001). Moreover, shift from PKA to CaMKII pathway is associated with
cardiac dysfunction and pathological ventricular remodeling (Schaper
et al., 1991).
In fact, a well-conducted study showed a direct cause–effect
relationship between CaMKII activity and impaired cardiac function
(Zhang et al., 2005). In our study, we observed an increased
phosphorylation of PLN at both Ser16 and Thr17, reﬂecting PKA and
CAMKII activation in HF, respectively. It is important to highlight that
sustained ARB treatment differentially affects the phosphorylation of
PLN at Ser16 or Thr17. ARB treatment further increased phosphoryla-
tion of PLN at Ser16 (main target of PKA) and decreased phosphor-
ylation of PLN at Thr17 (main target of CAMKII). The increased
phosphorylation of PLB at Ser16 by ARB treatment would favor the
signaling switch towards a predominant PKA pathway that together
with increased SERCA 2 expression take part of for ARB treatment-
related mechanisms underlying improved ventricular function in HF.
The increased protein levels of CaMKII and its activated form,
phospho-Thr286-CaMKII, paralleled by increased expression of phos-
pho-Thr17-PLN levels in placebo-treated α2A/α2CARKOmice reveal that
cardiac CaMKII pathway is over activated. Of interest, ARB treatment
not only decreased CaMKII expression but also reduced phospho-Thr17-
PLN protein levels and tended to decrease phospho-Thr286-CaMKII
Fig. 3. ARB therapy increases cardiac phospho-Ser16-PLN and decreases phospho-Thr17-PLN protein levels in HF. (A) Representative blots of phospho-Ser16-PLN, phospho-Thr17-PLN,
PP1 and GAPDH, (B) Phospho-Ser16-PLN, (C) Phospho-Thr17-PLN and (D) PP1 protein levels in WT, placebo- and ARB-treated ARKO mice. Note that placebo-treated ARKO
mice presented increased Phospho-Thr17-PLN expression. In addition, ARB treatment decreased Phospho-Ser16-PLN and Phospho-Thr17-PLN in ARKO mice. Data are presented as
means±SE. *Pb0.05 vs. WT; †P 0.05 vs. placebo-treated ARKO mice.
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cardiac function associated with sustained ARB treatment may be also
due to the diminished CAMKII pathway activation. We have recently
reported that CAMKII pathway is hyper-activated in sympathetic
hyperactivity-induced HF, and β-blocker therapy reduced its activation
and re-established cardiac function (Bartholomeu et al., 2008; Oliveira
et al., 2009). Since CAMKII is a well known substrate of angiotensin
II receptor-activated kinases (i.e. PKC and MAPK), it is reasonable to
speculate that sustained ARB treatment drastically reduces the
phosphorylation of downstream CAMKII targets.
Besides impaired cardiac contractile properties, HF is characterized
by progressive myocardial remodeling associated with cardiomyocyte
loss and ventricular ﬁbrosis. In fact, we observed cardiomyocyte
hypertrophy associated with increased collagen volume fraction in
α2A/α2CARKO mice. Sustained ARB treatment partially decreased
cardiomyocyte cross-sectional diameter and ventricular ﬁbrosis.
However, the mechanisms by which ARB treatment reverses cardiac
structural abnormalities in α2A/α2CARKO mice were not addressed in
the present study. In addition, the question of whether impaired Ca2+
handling and cardiomyocyte hypertrophy are isolated or interdepen-
dent phenomena is beyond the scope of the present study, but it is
undoubtedly an interesting topic for future investigations. The cellular
mechanisms underlying the beneﬁts of sustained ARB treatment
on ventricular function and remodeling in HF may be related to
inactivation of selective transmembrane G-protein-coupled recep-
tors-mediated kinases. Angiotensin II receptor-mediated protein
kinase C (PKC) activation has been related to decreased myocytecontractility and pathological hypertrophy in HF, whereas sustained
Angiotensin II receptor blockade abrogated the deleterious effects of
PKC activation in HF (Inagaki et al., 2002). Furthermore, pharmaco-
logical inhibition of PKCβII and PKCε isozymes displayed similar
response to ARB treatment in HF animal model (Palaniyandi et al.,
2009), resulting in improved calcium transient and better ventricular
function (Ferreira et al., 2008b).
Conclusions
The present ﬁndings provide, for the ﬁrst time, evidence that
sustained ARB treatment rearranged the network of cardiac Ca2+
handling proteins in sympathetic hyperactivity-induced HF mice. The
cardiac structural and functional abnormalities were also counter-
acted by ARB treatment underscoring the role of cardiac RAS
activation in this process. Taken together, these results provide new
insights on intracellular Ca2+ regulatory mechanisms underlying
improved cardiac function by sustained ARB treatment in HF.
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Fig. 4. ARB therapy reduces CaMKII and phospho-Thr286-CaMKII protein levels in HF.
(A) Representative blots of CaMKII, phospho-Thr286-CaMKII and GAPDH, (B) CaMKII
and (C) phospho-Thr286-CaMKII protein levels in WT, placebo- and ARB-treated ARKO
mice. Note that placebo-treated ARKOmice presented increased CaMKII expression and
ARB treatment was able to restore those levels to WT values. In addition, ARB-treated
ARKO mice presented a trend toward a decrease in values for phospho-Thr286-CaMKII
protein levels vs. placebo-treated ARKO mice. Data are presented as means±SE.
*Pb0.05 vs. WT.
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